• Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP
ERA-EDTA
  • ABOUT ERA-EDTA
      • WHO WE ARE
      • History
      • ERA-EDTA Facts and Dates
      • Pioneers of the European Nephrology
        • Interviews with the Masters of Nephrology
      • Obituaries
      • Mission
      • ORGANIZATION & GOVERNANCE
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
        • Candidatures Boards and Calls
      • ORGANIZATION & GOVERNANCE
      • Group & Staff
        • ERA-EDTA
          • ERA-EDTA Operative Headquarters
        • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Disclosure of Interest (DoI)
      • Annual Reports
      • Accounts
      • ERA-EDTA Membership
      • Benefits
      • Fees
      • Renewal
      • Members: Senior – Junior
      • Honorary Members
      • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Past Congresses
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Patient Information
      • Initiatives for patients
      • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
      • NDT
      • CKJ
      • Cardio-renal research
      • EDTA Proceedings
      • Newsletter & Press Releases
        • Nephrology News Flash
        • NEP Newsletter
        • Press Releases
      • News
      • EDTA Proceedings
      • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
      • National Societies of Nephrology List
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • Biomedical Alliance in Europe
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Search
  • Menu
  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
  • MEMBERSHIP
  • My Era-Edta
  • Contact us
  • ABOUT ERA-EDTA
    • Who we are
      • History
      • ERA-EDTA Facts and Dates
      • Mission
    • Organization & Governance
      • Council
        • Council Members
        • Past Council Members
        • Committees, Roles and Terms
    • Group & Staff
      • ERA-EDTA
      • ERA-EDTA Operative Headquarters
      • ERA-Eurocongress Ltd
      • Constitution
      • Code of Conduct
      • Annual Reports
      • Accounts
    • ERA-EDTA Membership
      • Benefits
      • Membership Fees
      • Renewal
      • Members: Senior – Junior
    • AWARDS
      • Awards 2020
      • Awards 2019
      • Awards 2018
      • ERA-EDTA Distinguished Fellow (FERA)
  • CONGRESS & MEETINGS
    • Berlin 2021
    • Paris 2022
    • Scientific and Educational Interaction Day (SEID)
    • CTDay
    • CEPD
    • ERA-EDTA CME Courses
  • VIRTUAL MEETING
  • SCIENCE
    • Long Term Fellowships
    • Research Programme
    • Registry Fellowships
    • Registry
    • ERACODA
  • EDUCATION
    • NEP-Nephrology Education Portal
    • Virtual Meeting
    • e-seminars
    • GlomCon Webinars
    • Short Term Clinical Fellowships
    • ERA-EDTA CME Courses
    • Initiatives for patients
    • Patient Associations
    • ERA-EDTA Endorsement/Non-Financial Support
    • European Specialty Examination in Nephrology (ESENeph)
    • COVID-19 News and Information
  • NETWORKING
  • GUIDELINES
  • JOURNALS & PRESS
    • NDT
    • CKJ
    • Cardio Renal Research
    • Newsletter & Press Releases
      • Nephrology News Flash
      • NEP-Nephrology Education Portal Newsletters
      • Press Releases
    • News
    • EDTA PROCEEDINGS
    • Press and Social Media Policies
  • PUBLIC AFFAIRS
    • Collaboration with Societies
    • National Societies
    • ASN ERA-EDTA ISN Collaboration
    • EKHA
    • ERA-EDTA Endorsement/Non-Financial Support
    • Link Exchange
  • Registry
  • ERBP
  • Working Groups
    • CKD-MBD
    • DESCARTES
    • DIABESITY
    • ERN
    • EUDIAL
    • EURECA-m
    • IWG
    • WGIKD
  • Committees
    • SAB
    • YNP
    • ECC
    • GNC
    • NPPC
    • Ethics Committee
    • Registry
    • ERBP

Experimental therapies for diabetic nephropathy

News-Home

Newer medications that are particularly promising for the treatment of diabetic nephropathy in the future include CCL2 and CCR2 inhibitors as well as anti-oxidative stress therapies such as NOX inhibitors.

There are several experimental therapies for diabetic nephropathy (DN) that are currently being tested. These include the use of existing medications such as pentoxifylline, allopurinol, SGLT2 inhibitors and GLP-1 agonists, and assessing their application in DN. Further newer medications that are particularly promising include CCL2 and CCR2 inhibitors as well as anti-oxidative stress therapies such as NOX inhibitors. With knowledge of the pathogenesis of DN expanding, new potential therapeutic targets are being discovered. Many of these are still in an early clinical trials stage, but results are promising. It is likely that within the next decade some of these will be available for clinical use; potentially providing new therapeutic options for the many patients who are affected by this devastating diabetic complication.

Find out more here

16 September 2019/by ERA-EDTA
Tags: diabetes, diabetic nephropathy
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on Linkedin
  • Share on Reddit
  • Share by Mail
  • Share on WhatsApp
https://www.era-edta.org/en/wp-content/uploads/2019/10/29.jpg 1081 1620 ERA-EDTA ERA-EDTA2019-09-16 11:32:072019-10-16 11:34:43Experimental therapies for diabetic nephropathy
You might also like
World Diabetes Day: Chronic Kidney Disease due to diabetes is a serious public health threat!
Diabetic kidney disease and podocyte lipotoxicity
Safety and effectiveness of bexagliflozin in patients with type 2 diabetes and CKD
Simultaneous pancreas-kidney (SPK) transplantation improves survival compared with kidney transplantation alone in patients with diabetes type 1
  • The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate19 October 2020 - 10:55
  • Are all donated kidneys the same?16 October 2020 - 11:40
  • Which phosphate transporters should be targeted to reduce hyperphosphatemia?14 October 2020 - 10:02
  • Does ADH modulate renal calcium excretion in patients with CDI and hypercalciuria?12 October 2020 - 16:31

ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org

ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom

You are here: Home / Experimental therapies for diabetic nephropathy

  • ABOUT ERA-EDTA
  • CONGRESS & MEETINGS
  • JOURNAL & PRESS
  • EDUCATION
  • PUBLIC AFFAIRS
  • GUIDELINES

  • My ERA-EDTA
  • Contact us
  • MEMBERSHIP
.av-share-box ul li{ display: none!important; }

  • Share on Facebook
  • Share on Twitter
  • Share on Pinterest
  • Share on Linkedin
  • Share on Reddit
  • Share by Mail
  • Share on WhatsApp
© Copyright - Era-Edta
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • Facebook
  • Instagram
  • Youtube
  • Linkedin
  • Twitter
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more